Elsevier

Human Pathology

Volume 31, Issue 2, February 2000, Pages 140-148
Human Pathology

Original Contribution
Intramucosal cysts in the gastric body of patients with Zollinger-Ellison syndrome*

https://doi.org/10.1016/S0046-8177(00)80213-0Get rights and content

To ascertain the frequency and the clinico-functional correlations of intramucosal cysts in the gastric body of patients with the Zollinger-Ellison syndrome (ZES) and to clarify the relevant mechanism of development, a total of 106 consecutive ZES patients (58 M, 48 F; mean age: 53 yrs, range 19–93 yrs) were investigated with a mean of 7.2 biopsy specimens of the body mucosa per patient proved to be suitable for the study. Biopsies of endoscopically detectable polypoid lesions were not considered. Cystic changes were evaluated with respect to their severity by assessing the cyst grade (0, absent, 1; <30%, 2; 30–60%; 3 >60% of the mucosal area of the biopsy specimen of individual patients showing the most pronounced finding, respectively) and to their intragastric distribution by assessing the ratio of biopsy specimens showing cystic changes over the total number of biopsies examined in each patient. Intramucosal cysts were found in biopsies of non-polypoid gastric body mucosa in 71.7% of 106 patients with Zollinger-Ellison syndrome (ZES) and showed grade 2 and 3 severity in 22 and 8 cases, respectively. The severity of cystic changes correlated with the gastrin levels (p = 0.0005) and was more advanced in patients with active than in those with cured disease (p = 0.037). In the former group, furthermore, advanced cystic changes correlated with age (p = 0.03), male gender (p = 0.014), years of disease from onset (p < 0.02), years of omeprazole treatment (p = 0.033), basal acid output (p < 0.02), severity of ECL cell proliferative changes (p = 0.028), and absence of previous gastrinoma resection (p = 0.039) whereas they did not correlate with MEN-1 status, gastritis, maximal acid output, total duration of any antisecretory drug treatment, daily doses of omeprazole (>20 mg vs 20 mg), years from surgery, duodenal localization of gastrinoma(s), presence of gastric carcinoid tumor(s) and of liver metastases. In groups of patients subdivided according to three levels of serum gastrin, the duration of omeprazole treatment was not related to the severity of cystic changes. It is concluded that intramucosal cysts in non polypoid gastric body mucosa of ZES patients are by far more common than the already reported fundic gland polyps, to which they likely give raise. Circulating levels of gastrin have an important independent role in their development.

References (29)

  • GrahamJR

    Gastric polyposis: Onset during long-term therapy with omeprazole

    Med J Aust

    (1992)
  • StolteM et al.

    Observation of gastric glandular cysts in the corpus mucosa of the stomach under omeprazole treatment

    Z Gastroenterol

    (1995)
  • El-ZimaityHM et al.

    Fundic gland polyps developing during omeprazole therapy

    Am J Gastroenterol

    (1997)
  • ChoudhryU et al.

    Proton pump inhibitor-associated gastric polyps: A retrospective analysis of their frequency, and endoscopic, histologic, and ultrastructural characteristics

    Am J Clin Pathol

    (1998)
  • Cited by (26)

    • Effect of chronic hypergastrinemia on human enterochromaffin-like cells: Insights from patients with sporadic gastrinomas

      2002, Gastroenterology
      Citation Excerpt :

      The corporal biopsy specimens were taken in a preset order: at the NIH, 4 specimens were taken from the greater curvature (3 at La Sapienza) and 4 from the lesser curvature (3 at La Sapienza).39,40 Biopsy specimens were fixed for 3–5 hours in Bouin's solution, rinsed with 70% ethyl alcohol and 30% water, and processed as described previously.39 Serial 5-μm-thick sections of gastric body mucosa perpendicular to the mucosal surface were stained with H&E for evaluation of the type of mucosa, with Giemsa stain for H. pylori evaluation, and with immunostaining for endocrine cells by using (1) monoclonal antibody against chromogranin A (clone LK2H10; Biogenex Laboratories, San Ramon, CA; working dilution 1:250) and (2) polyclonal rabbit antisera against the α-subunit of human chorionic gonadotropin (α-hCG; produced by Dr. H. Okumura, Teikoku Hormone Manufacturing Co., Kawasaki, Japan, donated by Dr. M. Fukayama, Department of Pathology, Tokyo Metropolitan Komagone Hospital, Tokyo, Japan; diluted 1:1600) as primary antibodies, with overnight incubation at 4°C.

    • Fundic gland polyps and gynecological malignancies [5]

      2001, American Journal of Gastroenterology
    • Gastric mucosal morphological consequences of acid suppression: A balanced view

      2001, Best Practice and Research: Clinical Gastroenterology
    View all citing articles on Scopus
    *

    Supported by grants from the Italian Association for Cancer Research (AIRC), Milan, and the Italian Ministry for University, Scientific and Technological Research (MURST).

    View full text